


## Quilseconazole

<b>Cat. No.:</b>	HY-109040	
<b>CAS No.:</b>	1340593-70-5	
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>14</sub> F <sub>7</sub> N <sub>5</sub> O <sub>2</sub>	
<b>Molecular Weight:</b>	513.37	
<b>Target:</b>	Fungal; Cytochrome P450	
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease	
<b>Storage:</b>	Powder	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (194.79 mM; Need ultrasonic)				
	Solvent Concentration	Mass	1 mg	5 mg	10 mg
<b>Preparing Stock Solutions</b>	1 mM		1.9479 mL	9.7396 mL	19.4791 mL
	5 mM		0.3896 mL	1.9479 mL	3.8958 mL
	10 mM		0.1948 mL	0.9740 mL	1.9479 mL
	Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Quilseconazole (VT-1129) is a potent, orally active fungal Cyp51 (lanosterol 14- $\alpha$ -demethylase) inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	CYP51

### REFERENCES

[1]. Lockhart SR, et al. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against *Cryptococcus neoformans* and *Cryptococcus gattii*.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA